Search results for "Hospital."

showing 10 items of 2242 documents

Prophylaxis of venous thromboembolism in elderly patients with multimorbidity

2013

none 327 si Pharmacological thromboprophylaxis (TP) is known to reduce venous thromboembolism (VTE) in medical inpatients, but the criteria for risk-driven prescription, safety and impact on mortality are still debated. We analyze data on elderly patients with multimorbidities admitted in the year 2010 to the Italian internal medicine wards participating in the REPOSI registry to investigate the rate of TP during the hospital stay, and analyze the factors that are related to its prescription. Multivariate logistic regression, area under the ROC curve and CART analysis were performed to look for independent predictors of TP prescription. Association between TP and VTE, bleeding and death in …

MaleTVPSettore MED/09 - Medicina InternaComorbidityLogistic regressionFondaparinuxVENOUS THROMBOEMBOLISM; THROMBOPROPHYLAXIS; Medical PatientsMedical patients; Thromboprophylaxis; Venous thromboembolism; Aged; Aged 80 and over; Area Under Curve; Comorbidity; Female; Hospital Mortality; Hospitalization; Humans; Logistic Models; Male; Propensity Score; Venous Thromboembolism; Internal Medicine; Emergency MedicineThromboprophylaxis Venous thromboembolism Medical patients80 and overHospital MortalityAged 80 and overSettore MED/45 - Scienze Infermieristiche Generali Cliniche E PediatricheMedical patients; Thromboprophylaxis; Venous thromboembolism; Aged; Aged; 80 and over; Area Under Curve; Comorbidity; Female; Hospital Mortality; Hospitalization; Humans; Logistic Models; Male; Propensity Score; Venous Thromboembolism; Internal Medicine; Emergency Medicineprophylaxis; venous thromboembolism; elderlyHospitalizationArea Under CurveEmergency MedicineFemaleprophylaxismedicine.drugVenous thromboembolismmedicine.medical_specialtyThromboprophylaxis; Venous thromboembolismmultimorbidityBarthel indexvenous thromboembolismMEDLINEMedical patients; Thromboprophylaxis; Venous thromboembolism; Aged; Aged 80 and over; Area Under Curve; Comorbidity; Female; Hospital Mortality; Hospitalization; Humans; Logistic Models; Male; Propensity Score; Venous Thromboembolism; Emergency Medicine; Internal Medicineelderly patientselderlyMedical patientsInternal medicineInternal MedicinemedicineHumansMedical prescriptionprophylaxis; venous thromboembolism; elderly patientsPropensity ScoreIntensive care medicineThromboprophylaxisAgedbusiness.industryprophylaxiMedical patients; Thromboprophylaxis; Venous thromboembolismprophylaxis; Venous thromboembolism; Elderly; multimorbidity; medical patients; thromboprophylaxismedicine.diseaseComorbidityLogistic ModelsPropensity score matchingbusinessVenous thromboembolism
researchProduct

A putative placebo analysis of the effects of LCZ696 on clinical outcomes in heart failure

2015

Aims: Although active-controlled trials with renin–angiotensin inhibitors are ethically mandated in heart failure with reduced ejection fraction, clinicians and regulators often want to know how the experimental therapy would perform compared with placebo. The angiotensin receptor-neprilysin inhibitor LCZ696 was compared with enalapril in PARADIGM-HF. We made indirect comparisons of the effects of LCZ696 with putative placebos.\ud \ud Methods and results: We used the treatment-arm of the Studies Of Left Ventricular Dysfunction (SOLVD-T) as the reference trial for comparison of an ACE inhibitor to placebo and the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidit…

MaleTetrazolesAngiotensin-Converting Enzyme InhibitorsEnalaprilEnalapril/therapeutic useMedicineNatriuretic peptidesAngiotensin IIAminobutyratesHeart Failure/CardiomyopathyMiddle AgedAngiotensin Receptor Antagonists/therapeutic useHospitalizationAngiotensin-Converting Enzyme Inhibitors/therapeutic useDrug CombinationsTreatment OutcomeTetrazoles/therapeutic useCardiologyValsartanFemaleCardiology and Cardiovascular Medicinemedicine.drugBenzimidazoles/therapeutic usemedicine.medical_specialtyAngiotensin II Type 1 Receptor Blockers/therapeutic usemedicine.drug_classPlaceboAngiotensin Receptor AntagonistsInternal medicineHumansEnalaprilFASTTrack Clinical ResearchBeta blockerAgedHospitalization/statistics & numerical dataHeart Failurebusiness.industryBiphenyl Compoundsmedicine.diseaseHeart Failure/drug therapyPlacebo EffectAngiotensin IICandesartanEndocrinologyAminobutyrates/therapeutic useHeart failureACE inhibitorBenzimidazolesbusinessAngiotensin II Type 1 Receptor BlockersSacubitril ValsartanNatriuretic peptide
researchProduct

Randomized comparison between clinical evaluation plus N-terminal pro–B-type natriuretic peptide versus exercise testing for decision making in acute…

2009

Background Exercise testing constitutes the usual tool for decision making in chest pain units. This policy implies logistical constrains. Our aim was to evaluate a new strategy, combining a clinical risk score and N-terminal pro–B-type natriuretic peptide (NT-proBNP), in patients presenting to the emergency department with chest pain, without ischemic electrocardiogram changes or troponin elevation. Methods A total of 320 patients were randomized to either usual management, involving exercise testing, or a new strategy combining a clinical risk score and NT-proBNP without exercise testing. In the usual management, discharge decision was guided by the result of exercise test. In the new str…

MaleThoraxChest Painmedicine.medical_specialtyRandomizationmedicine.drug_classPhysical exerciseChest painInternal medicineNatriuretic Peptide BrainNatriuretic peptideHumansMedicineProspective StudiesMyocardial infarctionbiologybusiness.industryEmergency departmentMiddle Agedmedicine.diseaseTroponinPatient DischargeHospitalizationAcute DiseaseExercise TestPhysical therapybiology.proteinFemalemedicine.symptomCardiology and Cardiovascular MedicinebusinessAmerican Heart Journal
researchProduct

Limitations of Clinical History for Evaluation of Patients With Acute Chest Pain, Non-Diagnostic Electrocardiogram, and Normal Troponin

2007

Decision making and risk stratification for patients with acute chest pain, nondiagnostic electrocardiogram results, and normal troponin levels are challenging. The aim of this study was to optimize the clinical history for the evaluation of these patients. A total of 1,011 patients presenting to an emergency department were included. The following data were collected: clinical presentation (pain characteristics and number of pain episodes), coronary risk factors, previous ischemic heart disease, and extracardiac vascular disease (peripheral artery disease, stroke, or creatinine >1.4 mg/dl). Two different predictive models were calculated according to the end points: model 1 for 1-year majo…

MaleThoraxChest Painmedicine.medical_specialtymedicine.medical_treatmentMyocardial InfarctionMyocardial IschemiaRevascularizationRisk AssessmentElectrocardiographySex FactorsRisk FactorsInternal medicineDiabetes MellitusMyocardial RevascularizationHumansMedicineMyocardial infarctionStrokePeripheral Vascular Diseasesmedicine.diagnostic_testbiologybusiness.industryVascular diseaseTroponin IAge FactorsModels CardiovascularEmergency departmentMiddle Agedmedicine.diseaseTroponinHospitalizationStrokeCreatinineAcute DiseaseExercise Testbiology.proteinCardiologyRegression AnalysisFemaleEmergency Service HospitalCardiology and Cardiovascular MedicinebusinessElectrocardiographyThe American Journal of Cardiology
researchProduct

Is high-sensitivity troponin, alone or in combination with copeptin, sensitive enough for ruling out NSTEMI in very early presenters at admission? A …

2019

Objectives: Copeptin and high-sensitivity cardiac troponin (HS-cTn) assays improve the early detection of non-ST-segment elevation myocardial infarction (NSTEMI). Their sensitivities may, however, be reduced in very early presenters.Setting: We performed a post hoc analysis of three prospective studies that included patients who presented to the emergency department for chest pain onset (CPO) of less than 6 hours.Participants: 449 patients were included, in whom 12% had NSTEMI. CPO occurred 4 hours in 146 patients. The prevalence of NSTEMI was similar in all groups (9%, 13% and 12%, respectively, p=0.281).Measures: Diagnostic performances of HS-cTn and copeptin at presentation were examined…

MaleTime Factors030204 cardiovascular system & hematologyChest pain0302 clinical medicinehigh sensitive cardiac troponinTroponin IMedicine1506Prospective Studies030212 general & internal medicineMyocardial infarctionNon-ST Elevated Myocardial InfarctionProspective cohort studynon st-elevation acute myocardial infarction[SDV.MHEP] Life Sciences [q-bio]/Human health and pathologyTroponin TRGlycopeptidesGeneral MedicineMiddle Aged3. Good healthchest pain onsetEmergency MedicineCardiologyMedicineFemalevery early presentersmedicine.symptomEmergency Service HospitalAdultmedicine.medical_specialtychest pain03 medical and health sciencesCopeptinPredictive Value of TestsInternal medicinePost-hoc analysisHumansAgedbusiness.industryResearchTroponin IcopeptinEmergency departmentmedicine.disease1691businessBiomarkers[SDV.MHEP]Life Sciences [q-bio]/Human health and pathology
researchProduct

A multicenter 12-month experience with a new iliac side-branched device for revascularization of hypogastric arteries.

2016

Abstract Objective The aim of this study was to investigate the 1-year safety and efficacy of a new iliac side-branched device (IBD) for revascularization of the hypogastric arteries. Methods Patients receiving the E-liac (Jotec GmbH, Hechingen, Germany) side-branched device at six German vascular centers either as a stand-alone procedure or in combination with abdominal aortic aneurysm exclusion were included in a prospectively created data bank. Collected data were analyzed for baseline characteristics, procedural events, and clinical follow-up; variables included endoleaks, reinterventions, and internal iliac artery (IIA) patency. Results Between January 2012 and January 2015, a total of…

MaleTime FactorsDatabases FactualEndoleakComputed Tomography Angiographymedicine.medical_treatmentBlood Loss Surgical030204 cardiovascular system & hematologyEndovascular aneurysm repair030218 nuclear medicine & medical imaging0302 clinical medicineRisk FactorsGermanyMedicineHospital MortalityAged 80 and overEndovascular ProceduresGraft Occlusion VascularArteriesMiddle AgedCommon iliac arteryInternal iliac arteryAbdominal aortic aneurysmTreatment OutcomeIliac AneurysmFemaleStentsRadiologyCardiology and Cardiovascular Medicinemedicine.medical_specialtyRevascularizationProsthesis DesignPelvis03 medical and health sciencesBlood Vessel Prosthesis ImplantationAneurysmBlood vessel prosthesismedicine.arteryHumansVascular PatencyAgedRetrospective Studiesbusiness.industryExternal iliac arteryAngiography Digital Subtractionmedicine.diseaseSurgeryBlood Vessel ProsthesisFeasibility StudiesSurgerybusinessJournal of vascular surgery
researchProduct

Intensive care unit strain should not rush physicians into making inappropriate decisions, but merely reduce the time to the right decisions being ma…

2016

The effect of capacity strain in an ICU on the timing of end-of-life decision-making is unknown. We sought to determine how changes in strain impact timing of new do-not-resuscitate (DNR) orders and of death.Retrospective cohort study of 9891 patients dying in the hospital following an ICU stay ≥72 h in Project IMPACT, 2001-2008. We examined the effect of ICU capacity strain (measured by standardized census, proportion of new admissions, and average patient acuity) on time to initiation of DNR orders and time to death for all ICU decedents using fixed-effects linear regression.Increases in strain were associated with shorter time to DNR for patients with limitations in therapy (predicted ti…

MaleTime FactorsDatabases Factualcommunication strategySeverity of Illness Indexlaw.invention0302 clinical medicinelawicuVasoconstrictor Agents030212 general & internal medicineHospital MortalityComputingMilieux_MISCELLANEOUSmedia_commonResuscitation OrdersAged 80 and overTerminal CaresupportGeneral MedicineMiddle AgedIntensive care unit3. Good healthIntensive Care UnitsEditorialqualityFemaleMedical emergencyof-life practicesAutonomyAdultmedicine.medical_specialtymedia_common.quotation_subjectCritical IllnessDecision Making03 medical and health sciencesQuality of life (healthcare)[ SDV.MHEP ] Life Sciences [q-bio]/Human health and pathologymedicineendHumansQuality (business)surrogateIntensive care medicineAgedRetrospective Studiescapacity strainbusiness.industry030208 emergency & critical care medicinefamily membersLength of Staymedicine.diseaseRespiration ArtificialcultureLinear Modelsbusiness[SDV.MHEP]Life Sciences [q-bio]/Human health and pathology
researchProduct

Retrograde Recanalization of Chronic Total Occlusions in Europe: Procedural, In-Hospital, and Long-Term Outcomes From the Multicenter ERCTO Registry.

2015

BACKGROUND A retrograde approach improves the success rate of percutaneous coronary interventions (PCIs) for chronic total occlusions (CTOs). OBJECTIVES The authors describe the European experience with and outcomes of retrograde PCI revascularization for coronary CTOs. METHODS Follow-up data were collected from 1,395 patients with 1,582 CTO lesions enrolled between January 2008 and December 2012 for retrograde CTO PCI at 44 European centers. Major adverse cardiac and cerebrovascular events were defined as the composite of cardiac death, myocardial infarction, stroke, and further revascularization. RESULTS The mean patient age was 62.0 +/- 10.4 years; 88.5% were men. Procedural and clinical…

MaleTime FactorsIncidenceMiddle AgedCoronary AngiographySettore MED/11 - Malattie Dell'Apparato CardiovascolareHospitalsEuropeElectrocardiographyPercutaneous Coronary InterventionPostoperative ComplicationsTreatment OutcomeCoronary Occlusionchronic total occlusionsJ-CTO scoreChronic DiseaseHumansretrograde PCI revascularizationFemaleHospital MortalityProspective StudiesRegistrieschronic total occlusionFollow-Up StudiesJournal of the American College of Cardiology
researchProduct

Incremental predictive value of mean platelet volume/platelet count ratio in in-hospital stroke after acute myocardial infarction.

2017

IF 2.558; International audience; Stroke is a serious complication after acute myocardial infarction (AMI) and is associated with an increased risk of death. Though the pathophysiological mechanisms are not exactly known, increased inflammation and platelet reactivity could play an important role in the occurrence of stroke during AMI. We aimed to investigate the relationship between both mean platelet volume (MPV), a parameter of platelet function, and C-reactive protein (CRP) and the occurrence of in-hospital ischemic stroke (IHS) after AMI. Data were obtained from a French regional survey for AMI that included 5976 patients admitted to an intensive care unit (ICU) between 2001 and 2010. …

MaleTime FactorsMESH : StrokeMyocardial InfarctionMESH : AgedMESH: ComorbidityComorbidityMESH: Hospitalization030204 cardiovascular system & hematologyMESH : Platelet Countlaw.inventionMESH: Proportional Hazards Models0302 clinical medicineMESH: Aged 80 and overRisk FactorslawMESH: Risk FactorsOdds Ratio[ SDV.MHEP.HEM ] Life Sciences [q-bio]/Human health and pathology/HematologyMESH : FemaleMyocardial infarctionMESH : BiomarkersStrokeMESH: Blood PlateletsAged 80 and overMESH: AgedEjection fractionMESH: Middle AgedMESH : PrognosisbiologyMESH : Mean Platelet Volume[SDV.MHEP.HEM]Life Sciences [q-bio]/Human health and pathology/HematologyHematologyGeneral MedicineMiddle AgedPrognosisIntensive care unitstrokeMESH : Risk Factors3. Good healthHospitalizationMESH: Myocardial Infarctionrisk factorplateletsMESH : ComorbidityCardiologyMESH : HospitalizationFemaleMean Platelet VolumeMESH : Time FactorsBlood Plateletsmedicine.medical_specialtyMESH : Male[SDV.BC]Life Sciences [q-bio]/Cellular BiologyAcute myocardial infarctionMESH: PrognosisMESH: StrokeC-reactive protein03 medical and health sciencesInternal medicinemedicineHumansMESH : Middle AgedMESH: Platelet Countcardiovascular diseasesRisk factorMean platelet volumeMESH : Aged 80 and overSurvival analysisAgedProportional Hazards ModelsMESH: HumansPlatelet Countbusiness.industry[ SDV.BC ] Life Sciences [q-bio]/Cellular BiologyC-reactive proteinMESH: Time FactorsMESH : HumansMESH : Blood Plateletsmedicine.diseaseMESH : Proportional Hazards ModelsMESH: Odds RatioMESH: MaleMESH: Mean Platelet Volumebiology.proteinMESH: BiomarkersMESH : Odds RatioMESH : Myocardial InfarctionbusinessMESH: FemaleBiomarkers030217 neurology & neurosurgery
researchProduct

Papillary muscle relocation in conjunction with valve annuloplasty improve repair results in severe ischemic mitral regurgitation

2012

OBJECTIVE: The incidence of recurrent mitral regurgitation (MR) after restrictive annuloplasty (RA) was 5% to 20% in several reports. There are many opinions in favor of adding subvalvular procedures to RA to reduce the tenting forces and improve the repair results. METHODS: From March 2003 to May 2010, 55 patients with severe ischemic MR who had undergone papillary muscle (PPM) relocation in conjunction with mitral annuloplasty in our institutions were enrolled. The patients were matched 1:1 with those who underwent isolated RA using the propensity score. The mean left ventricular ejection fraction was 42% ± 6%. The mean tenting area and coaptation depth was 3.2 ± 0.6 cm(2) and 1.3 ± 0.2 c…

MaleTime FactorsMitral Valve AnnuloplastyLeftMyocardial IschemiaKaplan-Meier EstimateSeverity of Illness IndexVentricular Function LeftPapillary muscle annuloplasty mitral regurgitationPostoperative ComplicationsRisk FactorsMitral valve annuloplastyAged; Chi-Square Distribution; Disease-Free Survival; Female; Hospital Mortality; Humans; Italy; Kaplan-Meier Estimate; Logistic Models; Male; Matched-Pair Analysis; Middle Aged; Mitral Valve Insufficiency; Myocardial Ischemia; Papillary Muscles; Postoperative Complications; Propensity Score; Proportional Hazards Models; Risk Assessment; Risk Factors; Secondary Prevention; Severity of Illness Index; Stroke Volume; Time Factors; Treatment Outcome; Ventricular Function Left; Mitral Valve AnnuloplastySecondary PreventionClinical endpointVentricular FunctionHospital MortalityMyocardial infarctionEjection fractionIncidence (epidemiology)Mitral Valve InsufficiencyMiddle AgedPapillary MusclesTreatment Outcomemedicine.anatomical_structureItalyCardiologyFemaleCardiology and Cardiovascular MedicinePulmonary and Respiratory Medicinemedicine.medical_specialtyMatched-Pair AnalysisRisk AssessmentDisease-Free SurvivalInternal medicinemedicineHumansPropensity ScorePapillary muscleAgedProportional Hazards ModelsMitral regurgitationChi-Square Distributionbusiness.industryStroke VolumeSettore MED/23 - Chirurgia Cardiacamedicine.diseaseSurgeryLogistic ModelsPropensity score matchingSurgerybusiness
researchProduct